FDA Approves Sanofi Aventis's Eloxatin
Eloxatin is the trade name for the generic drug name Oxaliplatin.
In some cases, health care professionals may use the trade name Eloxatin when referring to the generic drug name Oxaliplatin.
Drug type: Eloxatin is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Eloxatin is classified as an "alkylating agent." (For more detail, see "How this drug works" section below).
What Eloxatin is used for:
This medication is used to treat colon or rectal cancer that has spread (metastasized), it is often given in combination with other anticancer drugs (fluorouracil and leucovorin).
Eloxatin (oxaliplatin for injection), Sanofi-Synthelabo's new-generationplatinum drug, has been approved in the USA for the treatment of patients with advanced colorectal cancer. Specifically, the drug has been cleared for use in combination with 5-fluorouracil and leucovorin for patients with advanced colorectal cancer whose disease has progressed or recurred within six months of first-line treatment with 5-FU/LV and Pharmacia's topoisomerase inhibitor Campto (irinotecan).
Eloxatin is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the body. It is an antineoplastic and works by killing cancer cells and slowing tumor growth.
Eloxatin is used together with other cancer medications to treat colon and rectal cancer.
Eloxatin, administered as an injection in combination with infusional 5-fluorouracil (5-FU) and leucovorin (LV), is indicated for the treatment of metastatic colon or rectum carcinomas that have recurred or progressed within six months following first-line therapy of 5-FU/LV and irinotecan. Eloxatin received FDA approval faster than any other cancer treatment to date. It was approved under a special FDA program enabling the promising, and much needed, drug to be sold prior to proof of its ability to prevent or delay death.
Colorectal cancer, according to the American Cancer Society, is the second leading cause of malignancy-related death in the US, and there has been very little available in the way of effective treatment for patients with advanced stages of this disease. Eloxatin may provide a worth while option where there previously was none.